NasdaqGM:OMERPharmaceuticals
Why Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback
Omeros Corporation recently reported second-quarter and half-year 2026 results showing a move from net losses to net income of US$13.23 million and US$69.29 million respectively, while also completing a share repurchase of 843,187 shares for US$9.87 million under its December 2025 buyback program.
Alongside this earnings turnaround, Omeros expanded its board to nine members and added veteran financier Joseph Schocken to both the board and audit committee, potentially influencing capital...